United States v. Barry Cadden – Jury Returns Mixed Verdict in Trial of NECC Co-Founder
The jury returned its verdict this morning, finding Barry Cadden, co-founder of the now-defunct [...]
In October of 2015, Ferring Pharmaceuticals quietly initiated a voluntary, class 2 recall of Bravelle® (75 IU dose, injection-method, NDC 55566850506), for reasons of sub-potency. In other words, it did not contain the right amount of active ingredient.
The recall applies to Bravelle® products sold between March 27, 2014 and October 6, 2015. If you or a loved one experienced any of the following losses or injuries you may be entitled to compensation:
- You spent thousands of dollars on the ineffective Bravelle®.
- You spent tens of thousands of dollars on fertility procedures (such as in vitro fertilization or IVF) that were ineffective because Bravelle® did not help you adequately make or release eggs.
- You experienced undue physical pain and suffering and side effects from Bravelle®.
- You experienced other injuries from your use of Bravelle® such as failed pregnancies and fertilizations.
- You experienced other related emotional damages as a result of your use of Bravelle®.
- Loss of your opportunity to have any children because Bravelle® wasted valuable time.
Affected lots were distributed between March 27, 2014, and October 6, 2015. As of now, the following lots have been identified, but other lots may also have been affected:
H15815A-1 (07/31/2015)
H15815B-1 (08/31/2015)
H15815SMA-1 (07/31/2015)
H16998A-1 (08/31/2015)
H16998SMA-1 (08/31/2015)
K10008A-1 (01/31/2016)
K10008A-2 (01/31/2016)
K11813A-1 (01/31/2016)
K11813A-2 (01/31/2016)
K11813B-1 (04/30/2016)
K11813C-1 (04/30/2016)
K13031A-1 (05/31/2016)
K13031B-1 (05/31/2016)
K13031B-2 (05/31/2016)
K13503A-1 (05/31/2016)
K13503B-1 (06/30/2016)
K13503SMA-1 (05/31/2016)
K13512A-1 (06/30/2016)
K13512A-2 (06/30/2016)
K13921A-1 (06/30/2016)
K13921A-2 (06/30/2016)
K13921B-1 (06/30/2016)
K14616A-1 (08/31/2016)
K14616A-2 (08/31/2016)
K15917A-1 (08/31/2016)
K15917SMA-1 (08/31/2016)
K15917SMA-2 (08/31/2016)
K17006AA (09/30/2016)
K18201AA (12/31/2016)
K18202AA (12/31/2016)
L10403AA (12/31/2016)
L10403AB (08/31/2016)
L10840AA (01/31/2017)
L10992AA (01/31/2017)
Expiration Dates listed in Parenthesis
In some cases Ferring Pharmaceuticals has offered to pay victims the purchase price of Bravelle®. Don’t sacrifice your right to a full recovery for all of your damages just because you want a quick payment. You need a lawyer to get you full compensation.
Recent Posts about Drugs and Pharmaceuticals
URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY
URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY
In October[...]
Federal Judge Confirms $200 Million Settlement for Victims Injured by Tainted NECC Steroids
Springfield, Mass. - Yesterday, Federal Bankruptcy Judge Henry Boroff ruled in open court confirming[...]
Male Testosterone Supplements Linked to Increased Risk of Heart Attack & Stroke
Abbott Labs is under fire after several users of its Androgel® testosterone replacement drug cla[...]
Unexpected Breast Growth from Risperdal Traumatizes Young Men
Just before the first trial involving Risperdal® (Risperidone) began in Pennsylvania state court[...]
Andrews & Thornton Investigates ADHD Medications Linked to Priapism in Men
The FDA warns that a class of medications used to treat attention deficit hyperactivity disorder (AD[...]
Andrews and Thornton Hand-Delivers NECC Bankruptcy Claims
In order to guarantee proper and timely filing of over 150 claims in the New England Compounding[...]
New Law Helps Ensure Compounding Pharmacy Safety
The FDA has implemented a new law concerning compounding pharmacies that is designed to protect [...]